{"id":"edoxaban-plus-single-antiplatelet-agent","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL1269025","moleculeType":"Small molecule","molecularWeight":"548.07"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edoxaban is a direct Factor Xa inhibitor that disrupts the coagulation cascade by preventing thrombin generation. When combined with a single antiplatelet agent, this dual therapy targets both the coagulation and platelet pathways, reducing thrombotic risk in patients requiring combined anticoagulation and antiplatelet therapy. This combination is used in acute coronary syndrome or other conditions where both pathways require inhibition.","oneSentence":"Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:06.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (with single antiplatelet agent)"},{"name":"Stroke prevention in atrial fibrillation (with single antiplatelet agent in select patients)"}]},"trialDetails":[{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT03718559","phase":"PHASE4","title":"Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Gi-Byoung Nam","startDate":"2019-05-14","conditions":"Atrial Fibrillation, Coronary Artery Disease, Stable Angina","enrollment":1040}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Edoxaban plus Single Antiplatelet Agent","genericName":"Edoxaban plus Single Antiplatelet Agent","companyName":"Gi-Byoung Nam","companyId":"gi-byoung-nam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection. Used for Acute coronary syndrome (with single antiplatelet agent), Stroke prevention in atrial fibrillation (with single antiplatelet agent in select patients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}